FR2758331B1 - Nouveaux moyens pour le diagnostic, la prevention et le traitement vis-a-vis de contaminations ou d'infections par des virus a tropisme muqueux - Google Patents

Nouveaux moyens pour le diagnostic, la prevention et le traitement vis-a-vis de contaminations ou d'infections par des virus a tropisme muqueux

Info

Publication number
FR2758331B1
FR2758331B1 FR9700300A FR9700300A FR2758331B1 FR 2758331 B1 FR2758331 B1 FR 2758331B1 FR 9700300 A FR9700300 A FR 9700300A FR 9700300 A FR9700300 A FR 9700300A FR 2758331 B1 FR2758331 B1 FR 2758331B1
Authority
FR
France
Prior art keywords
tropism
mucous
infections
viruses
diagnosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR9700300A
Other languages
English (en)
Other versions
FR2758331A1 (fr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universite de Bourgogne
Original Assignee
Universite de Bourgogne
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universite de Bourgogne filed Critical Universite de Bourgogne
Priority to FR9700300A priority Critical patent/FR2758331B1/fr
Priority to PCT/FR1997/002433 priority patent/WO1998031807A1/fr
Priority to EP97953956A priority patent/EP0953050A1/fr
Publication of FR2758331A1 publication Critical patent/FR2758331A1/fr
Application granted granted Critical
Publication of FR2758331B1 publication Critical patent/FR2758331B1/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/11—Paramyxoviridae (F); Pneumoviridae (F), e.g. respiratory syncytial virus [RSV]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
FR9700300A 1997-01-14 1997-01-14 Nouveaux moyens pour le diagnostic, la prevention et le traitement vis-a-vis de contaminations ou d'infections par des virus a tropisme muqueux Expired - Fee Related FR2758331B1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
FR9700300A FR2758331B1 (fr) 1997-01-14 1997-01-14 Nouveaux moyens pour le diagnostic, la prevention et le traitement vis-a-vis de contaminations ou d'infections par des virus a tropisme muqueux
PCT/FR1997/002433 WO1998031807A1 (fr) 1997-01-14 1997-12-26 Nouveaux moyens pour le diagnostic, la prevention et le traitement vis-a-vis de contaminations ou d'infections par des virus a tropisme muqueux
EP97953956A EP0953050A1 (fr) 1997-01-14 1997-12-26 Nouveaux moyens pour le diagnostic, la prevention et le traitement vis-a-vis de contaminations ou d'infections par des virus a tropisme muqueux

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9700300A FR2758331B1 (fr) 1997-01-14 1997-01-14 Nouveaux moyens pour le diagnostic, la prevention et le traitement vis-a-vis de contaminations ou d'infections par des virus a tropisme muqueux

Publications (2)

Publication Number Publication Date
FR2758331A1 FR2758331A1 (fr) 1998-07-17
FR2758331B1 true FR2758331B1 (fr) 1999-03-05

Family

ID=9502577

Family Applications (1)

Application Number Title Priority Date Filing Date
FR9700300A Expired - Fee Related FR2758331B1 (fr) 1997-01-14 1997-01-14 Nouveaux moyens pour le diagnostic, la prevention et le traitement vis-a-vis de contaminations ou d'infections par des virus a tropisme muqueux

Country Status (3)

Country Link
EP (1) EP0953050A1 (fr)
FR (1) FR2758331B1 (fr)
WO (1) WO1998031807A1 (fr)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7635568B2 (en) 2000-11-28 2009-12-22 Medimmune, Llc Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
US7700735B2 (en) 2000-03-01 2010-04-20 Medimmune, Llc High potency recombinant antibodies and method for producing them
US7740851B2 (en) 2000-01-27 2010-06-22 Medimmune, Llc Ultra high affinity neutralizing antibodies
US7785592B2 (en) 2002-06-14 2010-08-31 Medimmune, Llc Stabilized liquid anti-RSV antibody formulations
US7847082B2 (en) 2000-11-28 2010-12-07 Medimmune, Llc Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
US8562996B2 (en) 2007-06-01 2013-10-22 Medimmune Limited RSV-specific binding molecules and means for producing them
US9283274B2 (en) 2009-10-06 2016-03-15 Medimmune Limited RSV specific binding molecule

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7425618B2 (en) 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9207479D0 (en) * 1992-04-06 1992-05-20 Scotgen Ltd Novel antibodies for treatment and prevention of respiratory syncytial virus infection in animals and man
DK0671927T3 (da) * 1992-09-16 2003-04-22 Us Gov Health & Human Serv Neutraliserende humane monoklonale antistoffer mod respiratorisk syncytialvirus
WO1995004081A1 (fr) * 1993-07-30 1995-02-09 Oravax, Inc. ANTICORPS IgA MONOCLONAL DIRIGE CONTRE LE VIRUS RESPIRATOIRE SYNCYTIAL
US5811524A (en) * 1995-06-07 1998-09-22 Idec Pharmaceuticals Corporation Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7740851B2 (en) 2000-01-27 2010-06-22 Medimmune, Llc Ultra high affinity neutralizing antibodies
US8153133B2 (en) 2000-03-01 2012-04-10 Medimmune, Llc High potency recombinant antibodies and method for producing them
US7700735B2 (en) 2000-03-01 2010-04-20 Medimmune, Llc High potency recombinant antibodies and method for producing them
US7635568B2 (en) 2000-11-28 2009-12-22 Medimmune, Llc Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
US7847082B2 (en) 2000-11-28 2010-12-07 Medimmune, Llc Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
US7785592B2 (en) 2002-06-14 2010-08-31 Medimmune, Llc Stabilized liquid anti-RSV antibody formulations
US8007793B2 (en) 2002-06-14 2011-08-30 Medimmune, Llc Stabilized liquid anti-RSV antibody formulations
US8206951B2 (en) 2002-06-14 2012-06-26 Medimmune, Llc Stabilized liquid anti-RSV antibody formulations
US8460663B2 (en) 2002-06-14 2013-06-11 Medimmune, Llc Stabilized liquid anti-RSV antibody formulations
US8986686B2 (en) 2002-06-14 2015-03-24 Medimmune, Llc Stabilized liquid anti-RSV antibody formulations
US9272032B2 (en) 2002-06-14 2016-03-01 Medimmune, Llc Stabilized liquid anti-RSV antibody formulations
US8562996B2 (en) 2007-06-01 2013-10-22 Medimmune Limited RSV-specific binding molecules and means for producing them
US9283274B2 (en) 2009-10-06 2016-03-15 Medimmune Limited RSV specific binding molecule

Also Published As

Publication number Publication date
EP0953050A1 (fr) 1999-11-03
FR2758331A1 (fr) 1998-07-17
WO1998031807A1 (fr) 1998-07-23

Similar Documents

Publication Publication Date Title
EP0776163A4 (fr) Enzymes codees par des bacteriophages, destinees au traitement et a la prevention de caries dentaires et de parodontolyses
FI964284L (fi) Apolipoproteiini E:n polymorfismi ja Alzheimerin taudin hoito
EP0630280A4 (fr) Procede d'elimination d'adn, de virus et d'endotoxines.
MA26790A1 (fr) Composition dietetique ou pharmaceutique a l'usage pour la prevention ou le traitement de la hyper-oxalurie
ZA964694B (en) Recombinant raccoon pox viruses and their use as an effective vaccine against feline immunodeficiency virus infection.
EP1039935A4 (fr) UTILISATION D'ACIDES NUCLEIQUES CONTENANT DES DINUCLEOTIDES CpG NON METHYLES DANS LE TRAITEMENT DES TROUBLES ASSOCIES AUX LIPOPOLYSACCHARIDES
AU1601595A (en) Device and process for removing leukocytes and viral inactivating agents from blood
DE69620220D1 (de) Antibakterielles mittel zur oralen verabreichung
DZ2028A1 (fr) Médicaments destinés au traitement d'infections bactériennes en pédiatrie.
MA26896A1 (fr) Utilisation de compositions d'antibiotiques azalides pour le traitement ou la prevention d'une infection par des bacteries ou protozoaires chez des mammiferes
EP1036844A4 (fr) Technique d'examen, reactif pour examen et medicament relatif a des affections provoquees par des modifications survenues dans le gene lkb1
ZA964679B (en) Genetically altered feline immunodeficiency viruses and their use as an effective vaccine against feline immunodeficiency virus infection.
FR2716881B1 (fr) Procédé de préparation et de purification d'Iopamidol.
IL114501A (en) Marek's disease virus vaccine
EE03514B1 (et) Ühendite kombinatsioon HIV infektsiooni või AIDS-i raviks, selle kasutamine ja farmatseutiline kompositsioon
FI963638A0 (fi) Menetelmiä HIV-1-injektion diagnosoimiseksi ja hoitamiseksi
ITVR940096A0 (it) Procedimento ed apparecchiatura per l'immunoadsorbimento specifico di virus hiv, di antigene gp120 e complesso cd4-gp120.
FR2721794B1 (fr) Plancher pourvu de moyen d'evacuation des excrements
EP1207550A4 (fr) Techniques d'attaque et de traitement au plasma
AU4259299A (en) New sequences of tt viruses for use in diagnosis, prevention and treatment of ttv infections
EE9600190A (et) Farmatseutiline kompositsioon viirusinfektsioonide ja võimalike kaasnevate põletike vältimiseks ja/või raviks ning nimetatud haiguste ravimeetod
ATE240123T1 (de) Radiopharmazeutische mittel zur bildgebung von infektionen und entzündungen
EP1435997A4 (fr) Technique de traitement d'une infection par le virus de l'hepatite c pour des patients dont le traitement a echoue
IT1289238B1 (it) Composizioni farmaceutiche per il trattamento di infezioni virali comprendenti una 4 arilcumarina
FR2718024B1 (fr) Médicament et composition pharmaceutique pour le traitement de l'inflammation.

Legal Events

Date Code Title Description
ST Notification of lapse

Effective date: 20091030